Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar in CKD (Daily Dosing)
NCT00048516Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Feb 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of paricalcitol oral solution in secondary hyperparathyroidism (SHPT), sponsored by Abbott Laboratories. Started Feb 2002; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00048516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048516.